# Novel Broad-Spectrum Point-of-Care Coagulometer

> **NIH NIH R44** · PEROSPHERE TECHNOLOGIES INC. · 2024 · $897,824

## Abstract

Project Summary/Abstract
Work under this proposal supports development of a broad-spectrum point-of-care (POC) coagulometer by
Perosphere Technologies (The Perosphere Technologies POC Coagulometer) with the intent to create and offer
an automated, microfluidic version of the manual Lee/White clotting time method. The device is based on novel
technology and utilizes reagent-less, single-use microfluidic cuvettes made of silicon and glass for measurement
of blood samples. Clot activation occurs at the beginning of the intrinsic clotting pathway through contact of a
blood sample with the inner glass and silicon surfaces of the cuvette. The device detects clot formation by
monitoring the intensity of near-infrared light, transmitted through cuvette and blood sample, and sensing of fibrin
assembly at the end of the common clotting pathway. The clot detection scheme affords development of two
main assays, a Clotting Time Assay, that measures the time to onset of clot formation and is currently
implemented on the coagulometer platform, and a Clot Lysis Time assay, that measures the time to onset of
subsequent clot breakdown and is in development. Research indicates that the device is broadly sensitive to
the effects of anticoagulants across drug class, their reversal agents and thrombolytic drugs. Initial marketing
efforts will focus on use of the device with implemented Clotting Time assay for monitoring of the direct oral
anticoagulants (DOACs) and low molecular weight heparins (LMWHs). Research under this proposal targets
establishment of clotting time reference ranges for healthy volunteers and patients on the DOACs rivaroxaban,
apixaban, dabigatran and edoxaban, in direct support of initial marketing goals. In support of future device
applications, the research also targets assessment of the device’s ability to detect inherited or acquired
coagulopathies, based on abnormal clotting times, as well as assessment of the device’s sensitivity to
abelacimab, a novel anticoagulant and direct factor XI/XIa inhibitor, currently in clinical development.
Perosphere Technologies intends to commercialize the device through a marketing, sales and distribution
partnership with a global medical device company. The device is similarly suited for use in emergency situations
(e.g. emergency room, emergency vehicle) and for routine care in the inpatient and outpatient settings (hospitals,
clinics, surgical suites, doctor’s offices, pharmacies) by healthcare professionals who can perform or order fresh
venous whole blood draws. The device promises to address several unmet medical needs, including point-of-
care monitoring of DOACs, and has the potential to define new standards of care. The device is expected to
improve patient care, clinical outcome and to reduce healthcare costs, by providing physicians with the means
to make faster and better-informed treatment decisions. The developed Clotting Time and Clot Lysis Time
assays will present a new way to describe a pati...

## Key facts

- **NIH application ID:** 10912646
- **Project number:** 5R44HL169158-02
- **Recipient organization:** PEROSPHERE TECHNOLOGIES INC.
- **Principal Investigator:** Sasha H Bakhru
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $897,824
- **Award type:** 5
- **Project period:** 2023-09-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10912646

## Citation

> US National Institutes of Health, RePORTER application 10912646, Novel Broad-Spectrum Point-of-Care Coagulometer (5R44HL169158-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10912646. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*